A detailed history of Comprehensive Financial Consultants Institutional, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Comprehensive Financial Consultants Institutional, Inc. holds 22,540 shares of BMY stock, worth $1.33 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
22,540
Previous 21,857 3.12%
Holding current value
$1.33 Million
Previous $907,000 28.56%
% of portfolio
0.45%
Previous 0.37%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

BUY
$39.66 - $51.75 $27,087 - $35,345
683 Added 3.12%
22,540 $1.17 Million
Q2 2024

Jul 17, 2024

BUY
$40.25 - $52.99 $147,113 - $193,678
3,655 Added 20.08%
21,857 $907,000
Q1 2024

May 02, 2024

BUY
$47.98 - $54.4 $61,414 - $69,632
1,280 Added 7.56%
18,202 $987,000
Q4 2023

Jan 24, 2024

BUY
$48.48 - $57.85 $116,448 - $138,955
2,402 Added 16.54%
16,922 $868,000
Q3 2023

Nov 13, 2023

SELL
$57.89 - $64.73 $8,220 - $9,191
-142 Reduced 0.97%
14,520 $842,000
Q2 2023

Jul 24, 2023

BUY
$63.71 - $70.74 $25,547 - $28,366
401 Added 2.81%
14,662 $937,000
Q1 2023

Apr 19, 2023

BUY
$65.71 - $74.53 $41,660 - $47,252
634 Added 4.65%
14,261 $988,000
Q4 2022

Jan 30, 2023

BUY
$68.48 - $81.09 $5,615 - $6,649
82 Added 0.61%
13,627 $980,000
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $130 - $77,301
1,006 Added 8.02%
13,545 $966,000
Q2 2022

Aug 09, 2022

SELL
$72.62 - $79.98 $5,664 - $6,238
-78 Reduced 0.62%
12,539 $940,000
Q1 2022

May 11, 2022

SELL
$61.48 - $73.72 $32,584 - $39,071
-530 Reduced 4.03%
12,617 $967,000
Q4 2021

Mar 10, 2022

BUY
$53.63 - $62.52 $705,073 - $821,950
13,147 New
13,147 $904,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Comprehensive Financial Consultants Institutional, Inc. Portfolio

Follow Comprehensive Financial Consultants Institutional, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comprehensive Financial Consultants Institutional, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Comprehensive Financial Consultants Institutional, Inc. with notifications on news.